loading
Schlusskurs vom Vortag:
$21.27
Offen:
$21.27
24-Stunden-Volumen:
46,398
Relative Volume:
0.07
Marktkapitalisierung:
$969.42M
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
14.88
EPS:
1.45
Netto-Cashflow:
$173.19M
1W Leistung:
-0.70%
1M Leistung:
-16.23%
6M Leistung:
-19.75%
1J Leistung:
+30.04%
1-Tages-Spanne:
Value
$20.96
$21.66
1-Wochen-Bereich:
Value
$20.50
$21.85
52-Wochen-Spanne:
Value
$16.00
$27.98

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name
Firmenname
Pacira Biosciences Inc
Name
Telefon
650-242-8052
Name
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Name
Mitarbeiter
790
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
PCRX's Discussions on Twitter

Vergleichen Sie PCRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
PCRX
Pacira Biosciences Inc
21.57 955.72M 681.75M 70.47M 173.19M 1.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
142.96 63.86B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.42 41.80B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.235 40.88B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.08 22.98B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
447.05 19.53B 3.08B 1.24B 1.07B 25.61

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-25 Hochstufung Truist Hold → Buy
2025-01-30 Hochstufung Truist Sell → Hold
2024-08-13 Herabstufung Truist Buy → Sell
2024-08-12 Herabstufung JP Morgan Overweight → Underweight
2024-08-12 Herabstufung Piper Sandler Overweight → Neutral
2024-08-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2024-08-12 Herabstufung Raymond James Outperform → Mkt Perform
2024-07-03 Herabstufung Barclays Overweight → Equal Weight
2024-03-07 Fortgesetzt JP Morgan Overweight
2023-12-20 Eingeleitet Raymond James Outperform
2023-08-03 Hochstufung TD Cowen Market Perform → Outperform
2023-01-31 Fortgesetzt Wedbush Outperform
2022-10-21 Fortgesetzt Jefferies Buy
2022-01-03 Fortgesetzt JP Morgan Overweight
2021-07-26 Hochstufung JP Morgan Neutral → Overweight
2021-04-21 Fortgesetzt JP Morgan Neutral
2021-04-09 Eingeleitet Berenberg Buy
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2021-02-11 Herabstufung Northland Capital Outperform → Market Perform
2021-01-21 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-09-21 Hochstufung Northland Capital Market Perform → Outperform
2020-07-06 Bestätigt Needham Buy
2020-05-27 Eingeleitet Guggenheim Neutral
2020-04-07 Eingeleitet Northland Capital Outperform
2020-03-20 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-02-24 Bestätigt H.C. Wainwright Buy
2020-01-24 Eingeleitet SunTrust Buy
2020-01-23 Eingeleitet SunTrust Buy
2019-11-06 Eingeleitet BTIG Research Buy
2019-06-11 Eingeleitet Barclays Overweight
2019-05-06 Hochstufung Mizuho Underperform → Neutral
2019-05-02 Hochstufung Stifel Sell → Hold
2019-02-01 Herabstufung Mizuho Neutral → Underperform
2018-08-06 Herabstufung BofA/Merrill Buy → Neutral
2018-04-09 Bestätigt H.C. Wainwright Buy
2018-03-21 Bestätigt Mizuho Neutral
2018-02-16 Herabstufung Needham Buy → Hold
2018-01-19 Eingeleitet Seaport Global Securities Buy
2018-01-04 Bestätigt Canaccord Genuity Buy
2018-01-03 Eingeleitet Leerink Partners Mkt Perform
Alle ansehen

Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten

pulisher
06:14 AM

Pacira BioSciences Inc. recovery potential after sell off2025 Market Overview & Community Consensus Stock Picks - newser.com

06:14 AM
pulisher
05:24 AM

How to integrate Pacira BioSciences Inc. into portfolio analysis toolsTrade Risk Report & AI Based Buy and Sell Signals - newser.com

05:24 AM
pulisher
02:12 AM

Real time social sentiment graph for Pacira BioSciences Inc.2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - newser.com

02:12 AM
pulisher
01:31 AM

Is Pacira BioSciences Inc. stock poised for growthBuy Signal & Free Accurate Trade Setup Notifications - newser.com

01:31 AM
pulisher
12:40 PM

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 - markets.businessinsider.com

12:40 PM
pulisher
12:27 PM

Chart based analysis of Pacira BioSciences Inc. trendsJuly 2025 Breakouts & Safe Swing Trade Setups - newser.com

12:27 PM
pulisher
Oct 30, 2025

Pacira BioSciences Inc. stock retracement – recovery analysis2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Pacira Biosciences, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Trends - Markets Mojo

Oct 30, 2025
pulisher
Oct 30, 2025

Pacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Pacira BioSciences (Nasdaq: PCRX) sets Nov. 6 third-quarter results; call at 4:30 p.m. ET - Stock Titan

Oct 30, 2025
pulisher
Oct 30, 2025

Will Pacira BioSciences Inc. stock keep outperforming rivalsMarket Sentiment Report & Technical Analysis for Trade Confirmation - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Can a trend reversal in Pacira BioSciences Inc. lead to recoveryGap Down & Precise Buy Zone Tips - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Why Pacira BioSciences Inc. (82P) stock could outperform next yearCEO Change & AI Based Buy and Sell Signals - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

What is the fair value estimate for Pacira BioSciences Inc. (82P) stock in 2025Market Trend Review & Weekly Momentum Stock Picks - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee - markets.businessinsider.com

Oct 29, 2025
pulisher
Oct 28, 2025

Building trade automation scripts for Pacira BioSciences Inc.July 2025 Setups & AI Forecast Swing Trade Picks - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Oct 28, 2025
pulisher
Oct 28, 2025

Pacira BioSciences, Inc. Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-To-Severe Osteoarthritis of the Knee - MarketScreener

Oct 28, 2025
pulisher
Oct 28, 2025

Pacira BioSciences (PCRX) Reports Promising Three-Year Findings for PCRX-201 - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Is Pacira BioSciences Inc. stock a buy on dipsForecast Cut & Smart Investment Allocation Insights - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 27, 2025

Pacira Biosciences Increceives Paragraph IV notice from Qilu Pharmaceutical - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Pacira BioSciences receives patent challenge for EXPAREL from Chinese firm - Investing.com

Oct 27, 2025
pulisher
Oct 27, 2025

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL® - The Manila Times

Oct 27, 2025
pulisher
Oct 27, 2025

Pacira BioSciences Receives PIV Notice from Qilu Pharmaceutical Regarding Generic EXPAREL Patent Claims - Quiver Quantitative

Oct 27, 2025
pulisher
Oct 27, 2025

Pacira BioSciences (NASDAQ: PCRX) notes PIV ANDA for EXPAREL; 45 days to file suit - Stock Titan

Oct 27, 2025
pulisher
Oct 27, 2025

How Pacira BioSciences Inc. stock trades before earnings2025 Risk Factors & Low Drawdown Momentum Ideas - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Oct 27, 2025

Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$46.78
price up icon 6.04%
drug_manufacturers_specialty_generic RDY
$13.30
price down icon 1.11%
$22.73
price up icon 0.69%
$10.38
price up icon 0.25%
$140.26
price up icon 1.07%
$447.88
price down icon 1.24%
Kapitalisierung:     |  Volumen (24h):